SYRE PE Ratio & Valuation,Is SYRE Overvalued

SYRE Relative Valuation

SYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SYRE is overvalued; if below, it's undervalued.

Historical Valuation

Spyre Therapeutics Inc (SYRE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.99. The fair price of Spyre Therapeutics Inc (SYRE) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：34.66

Fair

-11.56

-9.77

EV/EBITDA

Spyre Therapeutics Inc. (SYRE) has a current EV/EBITDA of -9.77. The 5-year average EV/EBITDA is -2.28. The thresholds are as follows: Strongly Undervalued below -8.03, Undervalued between -8.03 and -5.16, Fairly Valued between 0.59 and -5.16, Overvalued between 0.59 and 3.46, and Strongly Overvalued above 3.46. The current Forward EV/EBITDA of -9.77 falls within the Strongly Undervalued range.

-9.01

EV/EBIT

Spyre Therapeutics Inc. (SYRE) has a current EV/EBIT of -9.01. The 5-year average EV/EBIT is -2.64. The thresholds are as follows: Strongly Undervalued below -7.86, Undervalued between -7.86 and -5.25, Fairly Valued between -0.02 and -5.25, Overvalued between -0.02 and 2.59, and Strongly Overvalued above 2.59. The current Forward EV/EBIT of -9.01 falls within the Strongly Undervalued range.

0.00

Spyre Therapeutics Inc. (SYRE) has a current PS of 0.00. The 5-year average PS is 593.05. The thresholds are as follows: Strongly Undervalued below -3438.10, Undervalued between -3438.10 and -1422.52, Fairly Valued between 2608.63 and -1422.52, Overvalued between 2608.63 and 4624.21, and Strongly Overvalued above 4624.21. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-15.35

P/OCF

Spyre Therapeutics Inc. (SYRE) has a current P/OCF of -15.35. The 5-year average P/OCF is -5.36. The thresholds are as follows: Strongly Undervalued below -14.24, Undervalued between -14.24 and -9.80, Fairly Valued between -0.92 and -9.80, Overvalued between -0.92 and 3.53, and Strongly Overvalued above 3.53. The current Forward P/OCF of -15.35 falls within the Strongly Undervalued range.

-11.89

P/FCF

Spyre Therapeutics Inc. (SYRE) has a current P/FCF of -11.89. The 5-year average P/FCF is -4.45. The thresholds are as follows: Strongly Undervalued below -11.51, Undervalued between -11.51 and -7.98, Fairly Valued between -0.92 and -7.98, Overvalued between -0.92 and 2.61, and Strongly Overvalued above 2.61. The current Forward P/FCF of -11.89 falls within the Strongly Undervalued range.

Spyre Therapeutics Inc (SYRE) has a current Price-to-Book (P/B) ratio of 6.79. Compared to its 3-year average P/B ratio of -94.70 , the current P/B ratio is approximately -107.17% higher. Relative to its 5-year average P/B ratio of -55.60, the current P/B ratio is about -112.21% higher. Spyre Therapeutics Inc (SYRE) has a Forward Free Cash Flow (FCF) yield of approximately -6.21%. Compared to its 3-year average FCF yield of -114.47%, the current FCF yield is approximately -94.58% lower. Relative to its 5-year average FCF yield of -102.51% , the current FCF yield is about -93.95% lower.

6.74

P/B

Median3y

-94.70

Median5y

-55.60

-6.21

FCF Yield

Median3y

-114.47

Median5y

-102.51

Competitors Valuation Multiple

The average P/S ratio for SYRE's competitors is 0.00, providing a benchmark for relative valuation. Spyre Therapeutics Inc Corp (SYRE) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of SYRE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of SYRE in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Spyre Therapeutics Inc (SYRE) currently overvalued or undervalued?

What is Spyre Therapeutics Inc (SYRE) fair value?

SYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Spyre Therapeutics Inc (SYRE) is between to according to relative valuation methord.

How does SYRE's valuation metrics compare to the industry average?

What is the current P/B ratio for Spyre Therapeutics Inc (SYRE) as of Dec 16 2025?

As of Dec 16 2025, Spyre Therapeutics Inc (SYRE) has a P/B ratio of 6.79. This indicates that the market values SYRE at 6.79 times its book value.

What is the current FCF Yield for Spyre Therapeutics Inc (SYRE) as of Dec 16 2025?

As of Dec 16 2025, Spyre Therapeutics Inc (SYRE) has a FCF Yield of -6.21%. This means that for every dollar of Spyre Therapeutics Inc’s market capitalization, the company generates -6.21 cents in free cash flow.

What is the current Forward P/E ratio for Spyre Therapeutics Inc (SYRE) as of Dec 16 2025?

As of Dec 16 2025, Spyre Therapeutics Inc (SYRE) has a Forward P/E ratio of -11.66. This means the market is willing to pay $-11.66 for every dollar of Spyre Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Spyre Therapeutics Inc (SYRE) as of Dec 16 2025?

As of Dec 16 2025, Spyre Therapeutics Inc (SYRE) has a Forward P/S ratio of 0.00. This means the market is valuing SYRE at $0.00 for every dollar of expected revenue over the next 12 months.

SYRE Valuation